In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder
Pharmaceuticals · 18.11.2026 · 19 (11) · 1839
DOI: 10.3390/ph19111839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.11.2026. Verfasst von Duaa A. Aqeel und 6 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties.
Methods
Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment.
Results
Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities.
Conclusions
Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.
Förderung
- King Saud University
Zitieren
APA
Aqeel, D. A., Al-Mazroua, H. A., Alsaif, N. A., Alomar, H. A., Bakheit, A. H., Binjubair, F. A., & Al-Salem, H. S. (2026). In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder. Pharmaceuticals, 19(11), 1839. https://doi.org/10.3390/ph19111839
Vancouver
Aqeel DA, Al-Mazroua HA, Alsaif NA, Alomar HA, Bakheit AH, Binjubair FA, et al. In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder. Pharmaceuticals. 2026;19(11):1839. doi:10.3390/ph19111839
BibTeX
@article{Aqeel2026,
author = {Aqeel, Duaa A. and Al-Mazroua, Haneen A. and Alsaif, Nawaf A. and Alomar, Hatun A. and Bakheit, Ahmed H. and Binjubair, Faizah A. and Al-Salem, Huda S.},
title = {In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1839},
doi = {10.3390/ph19111839}
}
EUVIMED